Evangelos Terpos to Multiple Myeloma
This is a "connection" page, showing publications Evangelos Terpos has written about Multiple Myeloma.
Connection Strength
10.774
-
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J. 2021 08 02; 11(8):138.
Score: 0.453
-
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood. 2021 07 01; 137(26):3674-3676.
Score: 0.450
-
Covid-19 vaccination in patients with multiple myeloma: Focus on immune response. Am J Hematol. 2021 08 01; 96(8):896-900.
Score: 0.450
-
Controversies in the use of new bone-modifying therapies in multiple myeloma. Br J Haematol. 2021 Jun; 193(6):1034-1043.
Score: 0.433
-
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia. 2020 08; 34(8):2000-2011.
Score: 0.417
-
Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. Int J Cancer. 2019 07 15; 145(2):559-568.
Score: 0.380
-
Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice. Eur J Haematol. 2018 Oct; 101(4):556-565.
Score: 0.370
-
Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival. Ann Hematol. 2018 Sep; 97(9):1671-1682.
Score: 0.362
-
Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma. Blood Cancer J. 2018 05 11; 8(5):42.
Score: 0.362
-
Going the distance: Are we losing patients along the multiple myeloma treatment pathway? Crit Rev Oncol Hematol. 2018 Jun; 126:19-23.
Score: 0.359
-
Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting, 2017. Clin Lymphoma Myeloma Leuk. 2018 05; 18(5):321-334.
Score: 0.357
-
Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 2018 01 12; 8(1):7.
Score: 0.354
-
Biology and treatment of myeloma related bone disease. Metabolism. 2018 03; 80:80-90.
Score: 0.351
-
Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study. Eur J Haematol. 2018 Jan; 100(1):10-19.
Score: 0.349
-
Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma. Ann Hematol. 2017 Oct; 96(10):1707-1714.
Score: 0.343
-
Increased expression of platelet derived growth factor receptor ß on trephine biopsies correlates with advanced myeloma. J BUON. 2017 Jul-Aug; 22(4):1032-1037.
Score: 0.341
-
Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study. Br J Haematol. 2017 07; 178(1):61-71.
Score: 0.336
-
Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2016. Clin Lymphoma Myeloma Leuk. 2017 06; 17(6):329-339.
Score: 0.335
-
Emerging treatment approaches for myeloma-related bone disease. Expert Rev Hematol. 2017 Mar; 10(3):217-228.
Score: 0.332
-
The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016. Am Soc Clin Oncol Educ Book. 2016; 35:e407-17.
Score: 0.308
-
High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. Leuk Res. 2010 Mar; 34(3):399-402.
Score: 0.199
-
Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma. Leuk Lymphoma. 2005 Dec; 46(12):1699-707.
Score: 0.153
-
Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood. 2003 Aug 01; 102(3):1064-9.
Score: 0.127
-
Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells. J Cell Mol Med. 2019 12; 23(12):8010-8018.
Score: 0.100
-
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019 06; 20(6):e302-e312.
Score: 0.097
-
Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome. Ann Hematol. 2019 Jun; 98(6):1457-1466.
Score: 0.096
-
Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome. Ann Hematol. 2019 Jun; 98(6):1427-1434.
Score: 0.096
-
INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. Future Oncol. 2019 May; 15(13):1411-1428.
Score: 0.096
-
Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients. Leuk Lymphoma. 2019 03; 60(3):619-628.
Score: 0.095
-
Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. Blood Cancer J. 2018 11 07; 8(11):102.
Score: 0.094
-
Management of multiple myeloma bone disease: impact of treatment on renal function. Expert Rev Hematol. 2018 11; 11(11):881-888.
Score: 0.093
-
Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. Blood Cancer J. 2018 10 04; 8(10):95.
Score: 0.093
-
Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis. JAMA Oncol. 2018 10 01; 4(10):1389-1397.
Score: 0.093
-
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica. 2018 11; 103(11):1772-1784.
Score: 0.093
-
GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort study. Clin Exp Nephrol. 2019 Feb; 23(2):199-206.
Score: 0.092
-
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica. 2018 09; 103(9):1422-1432.
Score: 0.092
-
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. Clin Lymphoma Myeloma Leuk. 2018 10; 18(10):e401-e419.
Score: 0.091
-
Optimizing therapy in bortezomib-exposed patients with multiple myeloma. Expert Rev Hematol. 2018 06; 11(6):463-469.
Score: 0.091
-
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia. 2018 08; 32(8):1697-1712.
Score: 0.090
-
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America. J Med Econ. 2018 May; 21(5):525-536.
Score: 0.089
-
The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe. Expert Rev Hematol. 2018 03; 11(3):219-237.
Score: 0.089
-
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018 03; 19(3):370-381.
Score: 0.089
-
Rare manifestations of extramedullary myeloma: testicular plasmacytomas. Leuk Lymphoma. 2018 08; 59(8):2002-2004.
Score: 0.088
-
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica. 2018 02; 103(2):197-211.
Score: 0.088
-
The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. Blood. 2018 01 25; 131(4):464-467.
Score: 0.088
-
An overview of the role of carfilzomib in the treatment of multiple myeloma. Expert Opin Pharmacother. 2017 Dec; 18(17):1883-1897.
Score: 0.088
-
Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. Eur J Haematol. 2017 Nov; 99(5):409-414.
Score: 0.087
-
Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases. Leuk Lymphoma. 2018 04; 59(4):983-987.
Score: 0.086
-
Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy. Leuk Lymphoma. 2017 Oct; 58(10):2304-2309.
Score: 0.085
-
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017 04; 18(4):e206-e217.
Score: 0.084
-
Efficacy and safety of elotuzumab for the treatment of multiple myeloma. Expert Opin Drug Saf. 2017 Feb; 16(2):237-245.
Score: 0.083
-
Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. Br J Haematol. 2017 Mar; 176(5):783-795.
Score: 0.082
-
Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point. Haematologica. 2015 Aug; 100(8):e328-30.
Score: 0.073
-
How lenalidomide is changing the treatment of patients with multiple myeloma. Crit Rev Oncol Hematol. 2013 Oct; 88 Suppl 1:S23-35.
Score: 0.065
-
Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosis. Leuk Lymphoma. 2006 Aug; 47(8):1553-6.
Score: 0.040
-
Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events. Sci Rep. 2017 12 19; 7(1):17802.
Score: 0.022
-
Study of bone metabolism and angiogenesis in patients undergoing high-dose chemotherapy/autologous hematopoietic stem cell transplantation. Eur J Haematol. 2018 Feb; 100(2):131-139.
Score: 0.022